34. Infectious Disease Evaluation of the Potential Hematopoietic Stem Cell Transplant Donor

  1. Deepali Kumar MD, MSc, FRCPC and
  2. Atul Humar MD, MSc, FRCPC
  1. Staci A. Fischer MD, FACP, FIDSA1,2

Published Online: 5 MAY 2011

DOI: 10.1002/9781444397949.ch34

The AST Handbook of Transplant Infections

The AST Handbook of Transplant Infections

How to Cite

Fischer, S. A. (2011) Infectious Disease Evaluation of the Potential Hematopoietic Stem Cell Transplant Donor, in The AST Handbook of Transplant Infections (eds D. Kumar and A. Humar), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444397949.ch34

Editor Information

  1. Transplant Infectious Diseases, University of Alberta, Edmonton, Canada

Author Information

  1. 1

    The Warren Alpert Medical School of Brown University, Providence, RI, USA

  2. 2

    Transplant Infectious Diseases, Rhode Island Hospital, Providence, RI, USA

Publication History

  1. Published Online: 5 MAY 2011
  2. Published Print: 13 MAY 2011

ISBN Information

Print ISBN: 9780470658277

Online ISBN: 9781444397949

SEARCH

Keywords:

  • infectious disease evaluation - of potential hematopoietic stem cell transplant donor;
  • optional donor testing - hepatitis B NAT;
  • West Nile virus (WNV) NAT;
  • Trypanosoma cruzi antibody, donors from endemic areas (Mexico, Central America, South America);
  • Leishmania antibody or polymerase chain reaction (PCR) - in donors;
  • serologic testing of HSCT donors - within 30 days of donation;
  • no known risk of tuberculosis transmission - from donors with untreated latent TB infection, TB testing not necessary;
  • history of deferral for blood donation - those with prior corneal or dura mater transplantation;
  • human pituitary-derived growth hormone administration;
  • Toxoplasma antibody

Summary

This chapter contains sections titled:

  • Routine screening of all donors

  • Optional donor testing

  • Comments

  • Resources